To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Summary of Fulgent Genetics Conference Call Company Overview - **Company**: Fulgent Genetics (NasdaqGM:FLGT) - **Date**: November 10, 2025 - **Key Speakers**: Paul Kim, Brandon Perthuis Financial Performance - **Quarterly Revenue**: $84.1 million, exceeding internal and market expectations [2] - **Gross Margins**: Improved to approximately 44% from mid-20s two years ago [4] - **Non-GAAP Income**: Positive for the quarter, with guidance raised from $320 million to $325 million for the year [2] - **Sales Team Growth**: Anticipated growth of 25% in the sales team for 2026 [6] Business Segments Performance 1. Precision Diagnostics - **Growth Rate**: 16% growth driven by reproductive health and carrier screening products [13] - **Product Expansion**: Launch of a 1,000-gene carrier screening test, the largest in the market [13] - **New Offerings**: Introduction of whole genome sequencing with RNA, increasing diagnostic yield by 15%-30% [14][20] - **Market Position**: Strong presence in infertility clinics, with plans to penetrate OB-GYN market with NIPT tests [17][18] 2. Anatomic Pathology (AP) - **Performance**: Year-over-year growth despite a temporary decline due to billing software changes [3] - **Digital Pathology Investment**: Significant investments leading to operational efficiencies and the ability to recruit pathologists remotely [7][8] - **Sales Strategy**: Revamped compensation plans to incentivize new business growth [5] 3. Biopharma Services - **Market Expansion**: Transitioned from NGS to multi-omics, increasing addressable market [25] - **Pipeline Development**: Building a robust pipeline with long sales cycles, expected to stabilize in the future [26] Strategic Initiatives - **AI Integration**: Focus on operational efficiencies through automation and AI, expected to further improve gross margins [41] - **M&A Potential**: Future acquisitions are a priority, with a focus on high-probability success targets [45] - **Cash Position**: Projected cash balance of approximately $800 million by the end of 2025, allowing for continued investment in operations and potential buybacks [31][44] Future Outlook - **2026 Expectations**: Anticipated continued growth across all business segments, with specific focus on expanding the sales team and enhancing operational efficiencies [12][30] - **Therapeutics Development**: Ongoing projects in phase two and phase one, with significant catalysts expected in 2026 [34][35] Key Takeaways - Fulgent Genetics is positioned for strong growth with a diversified portfolio across precision diagnostics, anatomic pathology, and biopharma services - The company is leveraging technology and operational efficiencies to enhance profitability and market share - Strategic investments in sales and potential M&A opportunities are expected to drive future growth and innovation [46]

Core Insights - Fulgent Genetics, Inc. is scheduled to present at multiple upcoming investor conferences, including the UBS Global Healthcare Conference on November 10 and the Piper Sandler 37th Annual Healthcare Conference on December 2 [4] Company Overview - Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business [2] - The laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians [2] - The therapeutic development business focuses on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform [2] - The company aims to transition from a genomic diagnostic business to a fully integrated precision medicine company [2] Financial Performance - For the third quarter of 2025, Fulgent reported revenue of $84.1 million, representing a 17% year-over-year growth [6] - The company experienced a GAAP loss of $6.6 million, or $0.21 per share, while reporting a non-GAAP income of $4.5 million, or $0.14 per share [6]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Financial Data and Key Metrics Changes - Revenue in Q3 2025 totaled $84.1 million, an increase from $81.8 million in Q2 2025, reflecting a year-over-year growth of 15% [16][19] - Non-GAAP gross margin was 44.3%, while GAAP gross margin was 42.2%, showing year-over-year improvement due to streamlined operations [16][19] - GAAP loss for the quarter was $6.6 million, an improvement from a loss of $19 million in the prior quarter [17][19] - Adjusted EBITDA for Q3 was approximately $0.7 million, compared to a loss of $3 million in Q2 2025 [17][19] Business Line Data and Key Metrics Changes - Laboratory services revenue reached nearly $84 million, with precision diagnostics up 7.3% sequentially and 16.4% year-over-year [11][19] - Biopharma revenue increased by 15.4% sequentially and 83.4% year-over-year [11][19] - Anatomic pathology revenue decreased by 7.6% sequentially but increased by 7.2% year-over-year due to timing of collections [11][19] Market Data and Key Metrics Changes - The company has begun to see minimal revenue from its therapeutic development business, primarily related to IP licensing royalties [16][19] - The introduction of new services, such as ultra-rapid whole genome sequencing, is expected to significantly improve patient outcomes in the NICU [12][19] Company Strategy and Development Direction - The company is focused on scaling efficiently and driving innovation across its service offerings, with a commitment to R&D spending [19][20] - The launch of new products, including an enhanced whole genome sequencing service and the expansion of the Beacon carrier screening service, is aimed at strengthening market position [12][13][19] - The company raised its full-year 2025 revenue outlook to $325 million, representing a growth of 15% year-over-year [19][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress of both laboratory services and therapeutic development, raising the outlook for the remainder of 2025 [7][19] - The company anticipates continued improvement in operating margins driven by increased revenue and operational efficiencies [19][21] - Management highlighted the importance of AI technology in enhancing laboratory services efficiency and precision [10][19] Other Important Information - The company ended Q3 with approximately $787.7 million in cash and equivalents, with expectations to end 2025 with around $800 million [18][22] - The company has not repurchased any shares in Q3, with approximately $139.6 million remaining available for future repurchases [18][19] Q&A Session Summary Question: What is the ultimate operating margin target? - Management noted that gross margins were positively impacted by efficiencies and automation, with expectations for continued improvement in margins due to in-house AI technology development [24][25][27] Question: Can you elaborate on the timing issues in anatomic pathology? - Management confirmed that the decrease in revenue was due to timing issues related to collections, with improvements expected in the upcoming quarters [28][29] Question: How do new products support future growth? - Management expressed excitement about the launch of new products, particularly the ultra-rapid whole genome sequencing service, which is expected to penetrate the NICU market effectively [30][31] Question: What are the updates on FID-007 and its phase two trial? - Management expects to complete enrollment by the end of 2025 and present data at ESMO in 2026, with plans to move to phase three based on positive results [41][42][47]

Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the "Company" or "Fulgent") about future events based on current views and assumptions. Examples of forward-looking statements made in this presentation include, among others, those related to long-term upside or value, management of risk, anticipated growth and positioning, ad ...

Revenue Growth - Revenue increased by $12.3 million, or 17%, from $71.7 million in Q3 2024 to $84.1 million in Q3 2025[145]. - Revenue from laboratory services reached $83.9 million in Q3 2025, up 17% from $71.7 million in Q3 2024, driven by increases in precision diagnostics, anatomic pathology, and BioPharma services[145][146]. - Precision diagnostics revenue grew by $7.2 million, or 16%, in Q3 2025 compared to Q3 2024, attributed to growth in reproductive health services[145][146][147]. - Total revenue for the nine months ended September 30, 2025, was $239.3 million, a 16% increase from $207.3 million in the same period of 2024[146]. - BioPharma services revenue surged by 83% in Q3 2025 compared to Q3 2024, reflecting the timing of service projects[145][147]. - Revenue from non-U.S. sources increased by $0.4 million, or 7%, from $6.0 million in Q3 2024 to $6.5 million in Q3 2025[152]. Profitability and Loss - Operating loss improved to $(15.4) million in Q3 2025, a 10% reduction from $(17.1) million in Q3 2024[144]. - Net loss attributable to Fulgent decreased by $8.0 million, or 55%, from $(14.6) million in Q3 2024 to $(6.6) million in Q3 2025[144]. - Gross profit increased by $8.7 million, or 33%, from $26.8 million in Q3 2024 to $35.5 million in Q3 2025, with gross margin improving from 37% to 42%[156]. Expenses - Consolidated cost of revenue increased by $3.6 million, or 8%, from $45.0 million in Q3 2024 to $48.6 million in Q3 2025, with cost of revenue as a percentage of revenue rising from 58% to 63%[153][155]. - Research and development expenses for the therapeutic development segment increased by $2.0 million, or 41%, from $4.8 million in Q3 2024 to $6.8 million in Q3 2025[161]. - Selling and marketing expenses increased by $2.5 million, or 28%, from $9.1 million in Q3 2024 to $11.6 million in Q3 2025[165]. - General and administrative expenses increased by $2.4 million, or 11%, from $21.0 million in Q3 2024 to $23.3 million in Q3 2025[167]. Cash Flow and Financial Position - Cash, cash equivalents, restricted cash, and marketable securities totaled $787.7 million as of September 30, 2025, down from $828.6 million at the end of 2024[175]. - Cash used in operating activities for the nine months ended September 30, 2025, was $23.5 million, compared to $4.0 million for the same period in 2024, primarily due to the purchase of Investment Tax Credits for $31.7 million[181]. - Cash provided by investing activities for the nine months ended September 30, 2025, was $100.2 million, mainly from $132.9 million in maturities of marketable securities and $3.8 million from the acquisition of ANP[183]. - Cash used in financing activities for the nine months ended September 30, 2025, was $14.3 million, primarily related to $10.9 million for the repurchase of common stock[185]. - As of September 30, 2025, approximately $139.6 million remained available for future repurchases of common stock under the stock repurchase program authorized in March 2022[188]. - Cash used in operating activities increased significantly due to fluctuations in cash receipts and payments, influenced by demand for tests and product mix[181]. - The company did not need to draw on any credit facilities due to a strong cash position as of September 30, 2025[187]. Future Expectations - The company expects approximately $106.7 million in refunds from the IRS related to tax credits, anticipated to be issued before the end of 2025[140]. - The company expects research and development expenses to continue increasing as clinical trials progress for FID-007, FID-022, and other preclinical studies[164]. - The company expects to incur more operating expenses in the coming quarters due to planned clinical trials for FID-007 and FID-022, impacting cash flow[181]. - The company may seek additional capital through securities offerings or collaborations, which could lead to dilution for existing stockholders[178]. - The company may incur substantial costs in pursuing future capital, including investment banking and legal fees, which could impact growth plans[179]. Revenue Concentration Risks - A single customer contributed $19.2 million, or 23%, of total revenue in Q3 2025, highlighting revenue concentration risks[149]. - The company is focusing on increasing its customer base to mitigate revenue concentration risks[149]. Tax and Interest - Interest income was $7.9 million and $24.0 million for Q3 and the nine months ended September 30, 2025, respectively[170]. - The effective tax rate was 9% and 7% for Q3 and the nine months ended September 30, 2025, compared to 21% and 14% for the same periods in 2024[171].

Financial Performance - Revenue for Q3 2025 was $84.1 million, representing a 17% year-over-year growth[5] - GAAP loss for Q3 2025 was $6.6 million, or ($0.21) per share; Non-GAAP income was $4.5 million, or $0.14 per share[6] - GAAP gross profit was $35.5 million, with a GAAP gross margin of 42.2%; Non-GAAP gross profit was $37.2 million, with a Non-GAAP gross margin of 44.3%[5] - Revenue for Q3 2025 was $84,069,000, a 17.1% increase from $71,743,000 in Q3 2024[20] - Gross profit for Q3 2025 was $35,512,000, compared to $26,771,000 in Q3 2024, resulting in a gross margin of 42.2% versus 37.3%[20][23] - Operating loss for Q3 2025 was $15,350,000, an improvement from a loss of $17,079,000 in Q3 2024[20] - Net loss attributable to Fulgent for Q3 2025 was $6,608,000, compared to $14,648,000 in Q3 2024[21] - Non-GAAP income attributable to Fulgent for Q3 2025 was $4,521,000, down from $9,438,000 in Q3 2024[21] - Non-GAAP adjusted EBITDA for Q3 2025 was $708,000, compared to $351,000 in Q3 2024[22] - Total operating expenses for Q3 2025 were $50,862,000, compared to $43,850,000 in Q3 2024[20] - Non-GAAP operating margin for Q3 2025 was -4.2%, improving from -5.8% in Q3 2024[23] Guidance and Future Expectations - Full year 2025 revenue guidance raised to $325.0 million[5] - Full year 2025 EPS guidance updated to a GAAP loss of approximately ($1.70) per share and Non-GAAP income of approximately $0.30 per share[5] - The company expects to receive approximately $106 million in tax refunds prior to December 31, 2025, which may be delayed due to the current government shutdown[7] Assets and Cash Position - Cash, cash equivalents, restricted cash, and investments in marketable securities totaled $787.7 million at the end of Q3 2025[5] - Total assets as of September 30, 2025, were $1,214.6 million, with total stockholders' equity of $1,120.8 million[19] Research and Development - The company is advancing clinical trials for FID-007 and FID-022, demonstrating progress in therapeutic development[4] - Research and development expenses for Q3 2025 were $13,860,000, up from $11,783,000 in Q3 2024[20] Business Transformation - The company aims to transform from a diagnostic business into a fully integrated precision medicine company[12] Selling and Marketing Expenses - Selling and marketing expenses for Q3 2025 increased to $11,642,000 from $9,124,000 in Q3 2024[20]

Core Insights - Fulgent Genetics, Inc. reported its third quarter 2025 financial results, showing continued growth in its laboratory services and therapeutic development businesses, with a notable focus on clinical trials for cancer treatments [2][4]. Financial Performance - Revenue for Q3 2025 was $84.1 million, representing a 17% increase year-over-year [5][6]. - The company reported a GAAP loss of $6.6 million, or ($0.21) per share, while non-GAAP income was $4.5 million, or $0.14 per share [5][6]. - Adjusted EBITDA for the quarter was $0.7 million [6]. - For the full year 2025, Fulgent raised its revenue guidance to $325.0 million [5]. Operational Highlights - The company is advancing its clinical trials, particularly with FID-007, which has shown meaningful efficacy in treating head and neck cancer patients [4]. - Fulgent has initiated phase one dosing escalation for FID-022, showcasing the capabilities of its nano delivery technology platform [4]. Outlook - Fulgent expects to close 2025 with a healthy balance sheet, projecting a GAAP loss of approximately ($1.70) per share and non-GAAP income of $0.30 per share for the year [5][7]. - The company ended Q3 2025 with $787.7 million in cash, cash equivalents, restricted cash, and investments in marketable securities [5].

Core Insights - Fulgent Genetics, Inc. announced preliminary clinical data from its ongoing phase 2 clinical trial for FID-007 in combination with cetuximab for the second-line treatment of recurrent or metastatic head and neck cancer [1] Group 1: Company Overview - Fulgent Genetics is a technology-based company with established businesses in clinical diagnostics and therapeutic development [1] Group 2: Clinical Trial Information - The preliminary data cutoff for the ongoing phase 2 clinical trial was September 25, 2025 [1]